---
title: "AstraZeneca's breast cancer drug fails in late-stage trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298768423.md"
datetime: "2026-09-11T20:44:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298768423.md)
  - [en](https://longbridge.com/en/news/298768423.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298768423.md)
generator: "portal-rs"
---

# AstraZeneca's breast cancer drug fails in late-stage trial

Sept 11 (Reuters) - AstraZeneca’s (AZN.L) breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial, it said on Friday, marking a setback for the recently approved treatment.

U.S.-listed shares of AstraZeneca fell 3% in aftermarket trading.

The drug, branded as Etcamah, when tested in combination with another cancer treatment palbociclib, only showed a numerical improvement in previously untreated patients with a form of advanced breast cancer, the company said.

AstraZeneca said the trial data will be shared in due course.

Last week, the U.S. Food and Drug Administration gave accelerated approval for Etcamah to be used together with certain targeted cancer medicines known as CDK4/6 inhibitor.

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [AstraZeneca: SERENA-4 Trial Of Etcamah Palbociclib Combination Fails To Meet Primary Objective](https://longbridge.com/en/news/298875452.md)
- [AstraZeneca's drug combo helps lung cancer patients live longer in late-stage study](https://longbridge.com/en/news/298331381.md)
- [Olema selloff on AstraZeneca miss a buying opportunity, says Citi](https://longbridge.com/en/news/298869648.md)
- [Contineum, J&J's depression drug fails to meet mid-stage trial goal](https://longbridge.com/en/news/298959899.md)
- [AstraZeneca CFO Sarin gains 73 shares from 2021 performance share plan dividend equivalents](https://longbridge.com/en/news/299064766.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**